The new anti-cancer drug NMS-03305293 capsule, with the clinical trial registration number CTR20212544. The main researchers are Director Hu Xichun and Director Zhang Jian of the Affiliated Cancer Hospital of Fudan University. Patients in need can pay attention.

new anti-cancer drug NMS-03305293 capsule , the clinical trial registration number is CTR20212544, the main researchers are Director Hu Xichun and Director Zhang Jian of the Affiliated Cancer Hospital of Fudan University . Patients in need can pay attention.

Indications: locally advanced/metastatic HER2-negative breast cancer, epithelial ovarian cancer, castration-resistant prostate cancer (CRPC) or pancreatic cancer

Inclusion criteria:

1. No limit on men and women, age ≥18 years old;
2. ECOG physical fitness status 0-2 (Can walk freely and take care of yourself)
3. subjects must take effective contraceptive measures or abstinence

exclusion criteria:

1. cancer brain metastasis;
2. undergoes major surgery within 4 weeks before treatment, except for diagnostic surgery;
3. active gastrointestinal diseases (e.g., recorded gastrointestinal ulcers, Crohn's disease, ulcerative colitis or short bowel synthesis ) Or other syndromes that may affect drug absorption

Drug clinical trial registration and information disclosure platform

Drug clinical trial registration and information disclosure platform

Drug clinical trial registration and information disclosure platform

0 Hospitals carrying out this clinical drug research are shown in the figure above. There is no charge for drug treatment after enrollment. If you have any questions, please leave a message in the comment area to ask me